![]() |
Name |
3-(2-(1-hydroxy-1-methyl-ethyl)-6-methyl-2,3-dihydrobenzofuran-4-yloxy)-5-methylphenol
|
Molecular Formula | C19H22O4 | |
IUPAC Name* |
3-[[2-(2-hydroxypropan-2-yl)-6-methyl-2,3-dihydro-1-benzofuran-4-yl]oxy]-5-methylphenol
|
|
SMILES |
Cc1cc(O)cc(Oc2cc(C)cc3c2CC(C(C)(C)O)O3)c1
|
|
InChI |
InChI=1S/C19H22O4/c1-11-5-13(20)9-14(6-11)22-16-7-12(2)8-17-15(16)10-18(23-17)19(3,4)21/h5-9,18,20-21H,10H2,1-4H3
|
|
InChIKey |
NXECJMZOUKKGPN-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 314.38 | ALogp: | 3.9 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 58.9 | Aromatic Rings: | 3 |
Heavy Atoms: | 23 | QED Weighted: | 0.873 |
Caco-2 Permeability: | -4.806 | MDCK Permeability: | 0.00001570 |
Pgp-inhibitor: | 0.01 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.09 |
30% Bioavailability (F30%): | 0.036 |
Blood-Brain-Barrier Penetration (BBB): | 0.042 | Plasma Protein Binding (PPB): | 98.52% |
Volume Distribution (VD): | 0.592 | Fu: | 1.03% |
CYP1A2-inhibitor: | 0.393 | CYP1A2-substrate: | 0.464 |
CYP2C19-inhibitor: | 0.492 | CYP2C19-substrate: | 0.619 |
CYP2C9-inhibitor: | 0.216 | CYP2C9-substrate: | 0.937 |
CYP2D6-inhibitor: | 0.902 | CYP2D6-substrate: | 0.879 |
CYP3A4-inhibitor: | 0.185 | CYP3A4-substrate: | 0.451 |
Clearance (CL): | 11.346 | Half-life (T1/2): | 0.816 |
hERG Blockers: | 0.045 | Human Hepatotoxicity (H-HT): | 0.025 |
Drug-inuced Liver Injury (DILI): | 0.06 | AMES Toxicity: | 0.015 |
Rat Oral Acute Toxicity: | 0.036 | Maximum Recommended Daily Dose: | 0.937 |
Skin Sensitization: | 0.653 | Carcinogencity: | 0.09 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.424 |
Respiratory Toxicity: | 0.23 |